Acquisition - Summary of Fair Value of Consideration (Detail) - USD ($) |
9 Months Ended | |||
|---|---|---|---|---|
Jun. 11, 2018 |
Aug. 31, 2018 |
Aug. 31, 2019 |
Nov. 30, 2018 |
|
| Consideration | ||||
| Cash | $ 10,500,000 | |||
| Cord blood inventory earnout | $ 3,601,697 | $ 4,282,975 | ||
| Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | ||||
| Consideration | ||||
| Cash | $ 10,500,000 | |||
| Cryo-Cell common stock | 3,500,000 | |||
| Cord blood inventory earnout | 4,698,255 | |||
| Consideration | $ 18,698,255 |
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|